News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Mahlet Gizaw Tebeka, MS

Articles by Mahlet Gizaw Tebeka, MS

The Option Value of Innovative Treatments for Non–Small Cell Lung Cancer and Renal Cell Carcinoma

ByJulia Thornton Snider, PhD,Katharine Batt, MD, MSc,Yanyu Wu, PhD,Mahlet Gizaw Tebeka, MS,Seth Seabury, PhD

October 25th 2017

Option value is the benefit a therapy provides patients by enabling them to survive to the next innovation.

Latest Updated Articles

The Option Value of Innovative Treatments for Non–Small Cell Lung Cancer and Renal Cell Carcinoma
October 25th 2017

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access